Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · REVELATION BIOSCIENCES, INC. (REVB)

Revelation Q2 net loss widens to $3.3 million; cash covers operations into Q1 2027

Negative Impact 3 of 5 earnings Written later

Revelation Biosciences reported results for the three and six months ended June 30, 2026. The net loss for the quarter rose to $3.3 million from $2.4 million a year earlier, and cash and cash equivalents stood at $11.5 million, which the company says is sufficient to fund operations through the first quarter of 2027.

Key points

  • Q2 2026 net loss was $3.3 million, or $0.87 per share, versus $2.4 million, or $28.04 per share, in Q2 2025.
  • Six-month net loss was $6.3 million, versus $4.5 million for the same period in 2025.
  • Cash and cash equivalents were $11.5 million at June 30, 2026, up from $10.7 million at December 31, 2025, mainly due to net proceeds from the January 2026 warrant inducement.
  • Revelation said it is working to start enrollment in its Phase 2/3 acute kidney injury study by year-end.

The filing

CompanyREVELATION BIOSCIENCES, INC. (REVB)
Form8-K, current report
Filed with the SECAug 6, 2026, 4:19 PM ET
Accession number0001193125-26-338097

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.